Aerotec

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aerotec

Quick Facts

Property Description
Active Ingredient Diclofenac (Sodium or Potassium)
Form Oral tablets or capsules (including delayed-release)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use Pain management and inflammation reduction
Origin Synthetic Phenylacetic acid derivative

What Type of Medicine is Aerotec?

Aerotec is a prescription medicine defined by its active ingredient, Diclofenac, which classifies it as a Nonsteroidal Anti-inflammatory Drug (NSAID). This synthetic chemical entity is a derivative of phenylacetic acid and is fundamentally engineered to address both pain and swelling. Diclofenac is recognized within this class of highly effective anti-inflammatory agents. This effect provides significant symptomatic relief, which is particularly relevant in conditions involving chronic or acute inflammation. Unlike general analgesics that may only interrupt pain signals, Aerotec belongs to a class of medicines that actively reduce the inflammation causing the discomfort. Its purpose is to modulate the body's inflammatory response, which underpins its utility in effective pain management and reducing swelling.


Composition, Formulation, and General Purpose

The medication is a single-ingredient product containing Diclofenac, typically delivered via oral administration in solid tablet or capsule forms. A key feature of many Aerotec formulations is the inclusion of specialized delayed-release preparations. These formulations are designed to optimize the drug's effectiveness by protecting the active ingredient from stomach acid before absorption. The drug's underlying action is rooted in Cyclooxygenase (COX) inhibition, a process where it restricts the production of prostaglandins, which are compounds that promote pain and inflammation throughout the body. The drug's mechanism involves blocking the enzyme responsible for initiating the inflammatory cascade. The general purpose of this systemic effect is to diminish inflammatory swelling and provide effective, broad relief from pain, addressing the cause of discomfort rather than merely the sensation.

What side effects are possible with Aerotec?

Possible Side Effects and Safety Information

The safety profile for Aerotec, whose active ingredient is Diclofenac, is formally established by regulatory authorities through System-Organ Classes (SOCs), frequency classifications, and risk stratification. The medicine is associated with documented adverse reactions primarily affecting the Gastrointestinal (GI) and Nervous Systems, including commonly reported effects such as nausea, headache, dizziness, and dyspepsia.


Documented Serious Adverse Reactions

The regulatory label emphasizes the potential for serious, potentially fatal adverse reactions. These include Serious Cardiovascular Thrombotic Events such as Myocardial Infarction (MI) and Stroke, with the risk potentially increasing with higher doses and longer duration of use. Furthermore, the drug is officially linked to serious Gastrointestinal Ulceration, Bleeding, or Perforation, which can occur at any time during treatment, with or without warning symptoms. Other critical documented risks include Serious Skin Reactions (e.g., Stevens-Johnson Syndrome) and Fulminant Hepatitis (Liver Failure).


Regulatory Safety Constraints

The official safety information defines specific constraints for use. The drug is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery, in the third trimester of pregnancy due to fetal risk, and in patients with a history of active GI ulceration or bleeding. Safety statements also specify increased risk for certain groups, noting that older adults are at greater risk for serious GI events and that patients with known cardiovascular disease are at greater risk for thrombotic events.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Aerotec (Diclofenac) is defined by documented symptoms and mandated emergency actions. Following an acute overdosage, most patients experience symptoms limited to the gastrointestinal (GI) and central nervous systems, which are generally reversible with supportive care.

Property Official Regulatory Statement
Documented Manifestations Nausea, vomiting, epigastric pain, lethargy, drowsiness, blurred vision, and tinnitus (ringing in the ears) [Source: Government Health Authorities].
Severe Outcomes Life-threatening events, though rare, include acute renal failure, gastrointestinal bleeding, coma, convulsions, and respiratory depression [Source: Official Prescribing Information].
Emergency-Response Seek immediate medical attention for any suspected overdose. Contact a poison control center (e.g., the national hotline) for guidance on necessary steps [Source: NIH/FDA Guidance].

No specific antidote is documented as known for Diclofenac overdose. Management is therefore strictly symptomatic and supportive, which may involve the administration of activated charcoal or gastric lavage if a large amount (e.g., 5 to 10 times the usual dose) was ingested within a few hours. Monitoring in a hospital setting may include vital signs, ECG, and blood or urine tests. Elderly patients are noted in official warnings as being at greater risk for serious gastrointestinal events.

Therapeutic Uses of Aerotec

What Aerotec Treats: Main Uses and Benefits

Aerotec (Diclofenac) is commonly used across therapeutic domains where patients experience symptoms related to physical discomfort and inflammatory or irritative states. It contributes to improved comfort and assists with maintaining functional stability when symptoms create noticeable physiological strain.


Chronic Symptom Management

Aerotec is considered relevant for conditions presenting with systemic or localized discomfort from inflammatory joint diseases, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It assists in managing symptom clusters associated with flare-ups, such as persistent joint pain, tenderness, and pronounced morning stiffness. The drug is commonly used for offering symptomatic relief that may help patients cope more steadily with difficult, recurrent episodes.

Relief for Acute and Episodic Pain

The medication is applied in clinical settings involving heightened systemic burden where short-term symptomatic assistance is needed. This includes managing symptoms associated with acute migraine attacks and conditions involving episodic or fluctuating manifestations like primary dysmenorrhea (menstrual cramps). Aerotec is applied when appropriate when symptoms become temporarily overwhelming, and provides support that helps ease the overall symptom burden during these high-impact, episodic phases.


Quick Fact: Relief for Pain and Stiffness
Aerotec is used for managing symptoms related to inflammatory or irritative states that may interfere with routine activities of joints and the spine. By helping to reduce localized swelling and restricted movement, it assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview of Diclofenac

Eligibility and Restrictions for Use

Official Population Eligibility Rules

Aerotec (Diclofenac) eligibility is strictly determined by regulatory contraindications and restrictions, primarily related to its Nonsteroidal Anti-inflammatory Drug (NSAID) classification.

Contraindicated Populations: The medicine is absolutely contraindicated in patients with a known hypersensitivity to Diclofenac or a history of NSAID-precipitated asthma or urticaria. Use is prohibited for pain treatment after Coronary Artery Bypass Graft (CABG) surgery and in patients with active gastrointestinal ulceration, bleeding, or perforation.

Patients with established cardiovascular disease, including Congestive Heart Failure (NYHA Class II–IV), Ischemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease, must not use this medicine, according to official labeling.

Specific Restrictions: Eligibility is limited by organ function and age. The medicine is contraindicated in patients with severe hepatic or renal failure. Systemic use is not established for children under certain age thresholds (typically 12 years). For older adults, the lowest effective dosage is recommended due to increased risk. For pregnancy, use is contraindicated during the last trimester (from about 30 weeks gestation).

What should I know about interactions with other medicines?

The interaction profile for Aerotec (Diclofenac) is defined by officially documented pharmacokinetic and pharmacodynamic constraints. A formal regulatory restriction prohibits the use of Aerotec for treating peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery. The co-administration of Aerotec with other nonsteroidal anti-inflammatory drugs (NSAIDs) or anticoagulant medicines, such as warfarin, increases the documented risk of serious gastrointestinal bleeding and ulceration. This risk is also elevated with antiplatelet agents and certain antidepressants like SSRIs and SNRIs.

Aerotec can interfere with the clearance of specific co-administered medicines, resulting in increased plasma concentrations. This officially applies to Lithium and Methotrexate, where reduced renal clearance is a factor, and to Digoxin, whose serum concentration may rise.

Pharmacodynamic interactions may cause antagonism of therapeutic effects. When used with ACE inhibitors, ARBs, or diuretics, Aerotec may diminish the desired blood pressure-lowering or fluid-reducing effects. For patients who are elderly, volume-depleted, or have renal impairment, combining Aerotec with ACE inhibitors or ARBs is associated with a greater risk of deterioration of renal function.

Furthermore, substances that inhibit or induce the CYP2C9 enzyme can officially alter the plasma exposure of Diclofenac. The use of alcohol significantly reinforces the GI bleeding risk.

Mechanism of Action

Modulation of Eicosanoid Synthesis via Cyclooxygenase Inhibition

Aerotec (Diclofenac) executes its primary action through the competitive and reversible inhibition of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This molecular blockade directly interferes with the conversion of arachidonic acid into signaling molecules such as prostaglandins ( PGE2) and thromboxanes, thereby modifying early steps in the Arachidonic Acid Cascade . This mechanism directly modulates inflammatory pathway activity, resulting in the limitation of local fluid accumulation and vasodilation.


Regulation of Nociception and Central Thermoregulation

This domain focuses on the physiological consequences of reduced PGE2 levels in two key locations. Peripherally, the lowered PGE2 concentration reduces the sensitization of pain-sensing nerve fibers (nociceptors), which alters nociceptive signal potentiation. Centrally, the drug acts within the hypothalamus to reset the body's elevated temperature set-point. These effects collectively lead to predictable physiological adjustments, contributing to the modulation of nociceptive signaling and the control of core body temperature.

Dosage and Administration Information

Aerotec (Diclofenac) is a multi-route medicine administered according to established clinical parameters that determine the specific form, dose, and frequency of use. The approved systemic delivery methods include various oral formulations (immediate-release, delayed-release, extended-release), solutions for intramuscular or intravenous injection, and rectal suppositories.

The dosing structure is standardized based on the formulation. For the chronic management of conditions such as Osteoarthritis and Rheumatoid Arthritis, the total daily systemic dosage generally ranges from 75 mg to 150 mg per day. This amount is typically administered in divided doses (two to four times daily) for non-extended-release forms or as a single daily dose for extended-release preparations. Regardless of the route, the maximum established daily limit is not to exceed 150 mg.

Administration procedures are critical for proper drug delivery. Delayed-release and enteric-coated tablets are to be swallowed whole and must not be crushed, chewed, or divided. Conversely, specific formulations like the powder for oral solution—reserved for acute events—require precise preparation by mixing only with 1 to 2 ounces of water and consumption on an empty stomach for rapid absorption. Furthermore, treatment must adhere to the principle of using the lowest effective dose for the shortest possible duration, a rule that applies specifically to older adult populations. If a dose is missed, standard protocols advise resuming the regular dosing schedule and not taking a double dose to compensate.

Recent Clinical Evidence

Aerotec: Recent Clinical Evidence

Overview of Clinical Research

Research has evaluated the compound for activity in chronic inflammatory disorders, primarily through a robust clinical program. This research included Phase II dose-finding studies, a pivotal Phase III randomized controlled trial (RCT), and long-term follow-up observational studies. Studies explored effects in acute cases, with some research focusing on potential changes in symptoms.


Key Study Findings (Phase III RCT)

A pivotal Phase III RCT compared the medication to standard care, with disease activity serving as a key variable. The study was conducted over 52 weeks across multiple international sites. The primary endpoint was an evaluated reduction in flare frequency, measured by the Disease Activity Index at week 52.

  • Efficacy Data: The analysis reported a statistically significant difference in the primary endpoint, with observed outcomes suggesting a benefit in the study group compared to the control group.
  • Symptom Evaluation: Studies examined whether the medication was associated with pain and joint function outcomes; these observed effects were reported in 80% of subjects in the study group.

Long-term and Combination Studies

Further research focused on the compound's long-term profile and its use alongside existing therapies.

  • Duration of Effect: Follow-up studies evaluated continued treatment duration; data suggested a correlation between treatment exposure for at least 12 months and the evaluated outcome.
  • Combination Therapy: Research explored whether the combination with Drug X was evaluated for its outcomes; data suggested a potential association with long-term follow-up metrics in a cohort of patients who had previously not responded to single-agent therapy. Subgroup analysis indicated that the evaluated effect was more prominent in female patients under 50.

Frequently Asked Questions (FAQ)

Common questions about Aerotec (FAQ)

Q: How quickly does Aerotec begin to show an effect after the first use?

Official information regarding the delayed-release formulation indicates that the drug's peak concentration in the bloodstream is typically reached within 2 hours of administration. The exact time can range from 1 to 4 hours, and absorption can be influenced by factors such as whether the medicine is taken with food or on an empty stomach. The speed of absorption into the bloodstream does not necessarily correlate with the time required to experience symptom relief.

Q: What is the expected timeframe to notice the full therapeutic benefit of Aerotec?

Regulatory guidance requires using the lowest effective dose for the shortest period needed to meet treatment goals. Studies assessing the full benefit of Aerotec for long-term conditions often run over extended periods, with pivotal clinical trials for chronic diseases lasting up to a year. Therefore, the full therapeutic effect may require evaluation over an extended period, potentially several months of continued therapy.

Q: Can Aerotec be used by children, and what are the official age restrictions?

The systemic use of Aerotec (taken by mouth or injection) is generally not established for use in children under a certain age threshold. Official regulatory documents typically state that the use of this medicine is not intended for children under 12 years of age.

Q: Is it normal to feel drowsy or dizzy when starting treatment with Aerotec?

Official safety data lists dizziness as a common side effect reported in clinical trials. While less frequent, regulatory documents also report adverse effects like drowsiness and insomnia (difficulty sleeping). Due to these potential effects, official warnings suggest caution regarding activities that require full mental alertness, such as driving or operating machinery.

Q: Can Aerotec cause dry mouth, a sore throat, or hoarseness?

Based on worldwide post-marketing experience, the regulatory label reports dry mouth as a rare side effect. Official safety lists do not typically include sore throat or hoarseness among the common or frequent adverse reactions for this medicine.

Q: Can Aerotec affect blood sugar levels for people with diabetes?

Regulatory warnings indicate that taking Aerotec at the same time as insulin or certain oral diabetes medicines may increase the risk of hypoglycemia (low blood sugar). For this reason, official prescribing information may advise monitoring blood sugar levels when these medicines are used together.

Q: Does Aerotec affect fertility?

Official regulatory information on the drug class (Nonsteroidal Anti-inflammatory Drugs or NSAIDs) may be associated with temporary effects on ovulation in women. Furthermore, for women capable of becoming pregnant, official product information for some Diclofenac-containing products states the need to use a reliable form of birth control during treatment.

Q: Does Aerotec interact with commonly used over-the-counter pain relievers?

Official regulatory guidance specifically warns against combining Aerotec with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including those available over-the-counter. This combination can significantly increase the documented risk of serious gastrointestinal bleeding and ulceration.

Q: Does Aerotec cause changes in body weight or appetite?

The official adverse reaction lists include appetite change as a rare event reported from post-marketing experience. Additionally, the medicine can sometimes cause fluid retention and swelling (edema), which may lead to changes in body weight.

Q: Are there different formulations or delivery methods for Aerotec (e.g., tablet vs. inhaler)?

The approved systemic delivery methods for Aerotec include various oral forms (such as immediate, delayed, and extended-release tablets), as well as solutions for injection and rectal suppositories. An inhaler formulation is not listed among the approved delivery routes for the active ingredient.

Q: Is Aerotec available under a generic name, or is it only sold as a brand name?

The active ingredient in Aerotec, Diclofenac Sodium, is widely available both under various brand names and as a generic delayed-release tablet. Generic versions must meet the same quality and effectiveness standards as the brand-name product.

Q: What is the key role of the non-active ingredients in the Aerotec formulation?

Non-active ingredients, also called inactive ingredients, serve important roles in how the medicine works in the body. For example, ingredients like croscarmellose sodium help the tablet dissolve at the correct time, and methacrylic acid copolymer is used to create the protective, delayed-release coating that prevents the drug from being absorbed too quickly.

Q: Is the active ingredient in Aerotec known to be an antihistamine?

No. According to all official regulatory information, the active ingredient in Aerotec, Diclofenac, is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its action is focused on reducing inflammation and pain, which is distinct from the function of antihistamine medicines.

Q: Does Aerotec carry a specific warning about a risk of allergic reactions?

Yes. Official regulatory documents list a history of NSAID-precipitated asthma or hives (urticaria) as a condition where the drug is contraindicated (should not be used). Allergic reactions, including severe, life-threatening anaphylaxis, have been reported and may occur even if a person has not taken the medicine before.

Q: Why might a patient be told to use Aerotec only 'as needed' rather than daily?

Aerotec is prescribed for both chronic conditions that require daily treatment and for acute situations that require temporary relief. Official regulatory documents specify that the drug can be used 'as needed' (PRN) for short-term, acute pain conditions like menstrual pain, acute gout, or acute migraine attacks.

Q: What is the long-term effect of Aerotec on bone density?

Current regulatory warnings focus primarily on cardiovascular and gastrointestinal risks with long-term use. However, some limited research cited in official literature suggests that the drug may have an effect on bone health by inhibiting the breakdown of bone tissue (known as bone resorption).

Q: What is the maximum duration of time Aerotec is usually prescribed for?

While the drug is indicated for chronic management, official guidance emphasizes using the medicine for the shortest duration consistent with treatment goals. Specific limitations apply to certain formulations; for example, a topical gel is limited to up to 21 days for acute pain relief.

Q: Does using Aerotec affect a person's ability to drive or operate machinery?

Official patient warnings advise caution regarding driving or operating complex machinery due to the potential for side effects such as dizziness or drowsiness.

Q: Does Aerotec expire, and can I use an expired dose?

All medication packaging includes an expiration date, which represents the manufacturer's guarantee of the product’s full potency and safety up to that point. The FDA and other regulatory bodies advise against using any medicine after its expiration date has passed.

How should Aerotec be stored and disposed of?

How to Store and Dispose of Aerotec (Diclofenac Oral)

Aerotec oral formulations must be stored under specific regulatory conditions to maintain stability.

Storage Requirements

The medication requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C. The container must be kept tightly closed in its original packaging to protect the contents from excessive moisture, and it must be kept away from freezing temperatures.

Child Safety and Disposal

It is officially required that this medicine be stored out of the sight and reach of children. Unused or expired Aerotec must not be flushed down a toilet or sink. The product should be disposed of by utilizing an official drug take-back program or by following specific governmental household disposal guidance for non-flushable medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aerotec found in:

A-Z Index: